

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6826)**

## **ANNOUNCEMENT ON ADJUSTMENT OF SHARE PRICE CAP FOR REPURCHASE OF A SHARES**

References are made to the announcements dated 24 August 2023 and 15 September 2023 and the circular dated 29 August 2023 (the “**Circular**”) of Shanghai Haohai Biological Technology Co., Ltd.\* (the “**Company**”) in relation to the plan on repurchase of A shares of the Company (the “**A Share(s)**”) through centralized bidding trading. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

On 24 August 2023, the board of directors of the Company (the “**Board**”) approved the plan on repurchase A Shares through centralized bidding trading (the “**Repurchase Plan**”). The Repurchase Plan was approved by the Shareholders by way of special resolutions at the extraordinary general meeting and the Class Meetings held on 15 September 2023. Pursuant to the Repurchase Plan, the Company will repurchase the A Shares through centralized bidding trading within 12 months from the date on which the Shareholders approve the Repurchase Plan at the extraordinary general meeting and the Class Meetings (the “**Repurchase Period**”). The total amount of funds for the Share Repurchase shall be not less than RMB100 million (inclusive) and not more than RMB200 million (inclusive), and the repurchase price shall not exceed RMB130.00 per A Share (inclusive). According to the Repurchase Plan and the Company’s Repurchase Report on the Repurchase of A Shares of the Company through Centralized Bidding Trading, if the Company conducts ex-rights and ex-dividend matters during the Repurchase Period, such as the conversion of capital reserve into share capital, cash dividends, bonus issue, allotment of shares, share subdivision or share reduction, the Company will adjust the cap of the repurchase price accordingly in accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.

On 29 May 2024, the Company’s 2023 Profit Distribution and Capital Reserve Capitalization Plan has been considered and approved at the 2023 Annual General Meeting, the 2024 first A shareholders’ class meeting and the 2024 first H shareholders’ class meeting of the Company, respectively. Accordingly, the Company will distribute a final dividend of RMB1.00 per Share (tax inclusive) to the Shareholders for the year ended 31 December 2023 (the “**Final Dividend Distribution**”) and will issue Capitalization Shares on the basis of 4 Capitalization Shares for every existing 10 Shares out of its reserves to the Shareholders (the “**Capitalization Issue**”).

In view of the completion of the Final Dividend Distribution of A Shares and the Capitalization Issue of A Shares of the Company on 20 June 2024 (being the ex-right and ex-dividend date of the A Shares), the Company has adjusted the cap of the repurchase price of A Shares accordingly in accordance with the relevant provisions of the Repurchase Plan. After adjustment, the repurchase price of A Shares was adjusted from no more than RMB130.00 per A Share (inclusive) to no more than RMB92.48 per Share (inclusive).

Save for the aforesaid adjustment, there is no change in other matters of the Repurchase Plan. The Company will continue to follow the Rules on Repurchase of Shares by Listed Companies (《上市公司股份回購規則》), the Self-Regulatory Guidelines No. 7 for Listed Companies on the Shanghai Stock Exchange – Share Repurchases (《上海證券交易所上市公司自律監管指引第7號 – 回購股份》) and other relevant regulations and the Repurchase Plan, select the opportunity to repurchase the shares according to the market situation during the Repurchase Period, and perform its information disclosure obligation in a timely manner according to the progress of the Share Repurchase.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
**Hou Yongtai**  
*Chairman*

Shanghai, the PRC, 20 June 2024

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.*

\* *For identification purpose only*